Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-313 in Peritoneal Carcinomatosis
NCT04047771Phase 1Terminated
- Sponsor
- Clover Biopharmaceuticals
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilunermin alfa in peritoneal carcinomatosis (PC), sponsored by Clover Biopharmaceuticals. Primary endpoints: Dose Limiting Toxicity at 21 days and Occurrence of adverse events and serious adverse events at 21 days. Started Sep 2019; status: terminated.
02
Drugs
rilunermin alfa
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT04047771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047771.